Erin Rudsinski - ESSA Pharma Executive
| EPIXDelisted Stock | USD 0.20 0.00 0.00% |
Executive
Erin Rudsinski is Executive of ESSA Pharma
| Phone | 778 331 0962 |
| Web | https://www.essapharma.com |
ESSA Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1525) % which means that it has lost $0.1525 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2125) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities.ESSA Pharma currently holds 329.26 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. ESSA Pharma has a current ratio of 42.56, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ESSA Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dr Cobuzzi | CervoMed | 60 | |
| Steven Colletti | Frequency Therapeutics | 58 | |
| William JD | CervoMed | 43 | |
| Kelly MHA | CervoMed | 62 | |
| Matthew Winton | CervoMed | 48 | |
| George Gianakopoulos | Biora Therapeutics | 63 | |
| Vineet MBA | Frequency Therapeutics | 43 | |
| Ravi Ramadas | Frequency Therapeutics | N/A | |
| Olukemi MD | Frequency Therapeutics | 50 | |
| Kevin Howe | Biora Therapeutics | N/A | |
| Anna Biehn | COSCIENS Biopharma | N/A | |
| Stephanie Engels | Frequency Therapeutics | N/A | |
| PharmD JD | Frequency Therapeutics | N/A | |
| Gaozhong Zhu | Frequency Therapeutics | N/A | |
| Todd Chappell | Frequency Therapeutics | 51 | |
| Michel Eng | COSCIENS Biopharma | N/A | |
| Shelby JD | Frequency Therapeutics | 49 | |
| Robyn Hatton | Biora Therapeutics | N/A | |
| Todd MBA | Frequency Therapeutics | 53 | |
| Mark Rosch | CervoMed | 62 | |
| James MBA | Biora Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.21 | |||
| Return On Asset | -0.15 |
ESSA Pharma Leadership Team
Elected by the shareholders, the ESSA Pharma's board of directors comprises two types of representatives: ESSA Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ESSA. The board's role is to monitor ESSA Pharma's management team and ensure that shareholders' interests are well served. ESSA Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ESSA Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Rudsinski, Executive | ||
| Jim Bristol, Consultant | ||
| CMA CPA, Chief Officer | ||
| Roger Ulrich, Consultant | ||
| Kim Hewitt, Consultant | ||
| Neil Thapar, Executive | ||
| Alessandra MD, Chief Officer | ||
| Erica Osbourne, Executive | ||
| Steve Pondell, Executive | ||
| Stephen MD, Consultant | ||
| Terry Schuenemeyer, Executive | ||
| MS MBA, Executive COO | ||
| Nkengyal Barber, Executive | ||
| Chandtip Chandhasin, Executive | ||
| Loleta Harris, Executive | ||
| David MD, CEO and President and Director | ||
| Kally Singh, Consultant |
ESSA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ESSA Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.15 | |||
| Current Valuation | (99.33 M) | |||
| Shares Outstanding | 47.31 M | |||
| Shares Owned By Insiders | 5.61 % | |||
| Shares Owned By Institutions | 73.70 % | |||
| Number Of Shares Shorted | 1.35 M | |||
| Price To Earning | (1.12) X | |||
| Price To Book | 0.09 X | |||
| EBITDA | (28.45 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in ESSA Stock
If you are still planning to invest in ESSA Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ESSA Pharma's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |